It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback